Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer.
Total raised: $60M
Founded date: 2010
Investors 2
| Date | Name | Website |
| 08.11.2023 | ARCH Ventu... | archventur... |
| 30.01.2023 | SR One | srone.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.12.2024 | Series A | $60M | - |
Mentions in press and media 4
| Date | Title | Description |
| 20.12.2024 | Akamis Bio: Tumor-Specific Immuno-Gene Company Closes $60 Million (Series A) | Akamis Bio – a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene (T-SIGn) therapy platform to deliver novel immunotherapeutic proteins, biomolecules, and transgene combinations to treat solid tumors – announced ... |
| 17.12.2024 | Akamis Bio Raises $60M in Funding | Akamis Bio, a Cambridge, MA-based clinical-stage oncology company, raised $60M in funding. The round was led by Sedgwick Yard. The company intends to use the funds to support its work to advance NG-350A through a Phase 1b clinical proof-of-... |
| 17.12.2024 | Promeet Raises $3.1M in Pre-Seed Funding to Transform Creator Monetization | Dubai, United Arab Emirates, December 17th, 2024, Chainwire Promeet, a platform designed to empower creators to monetize content, has successfully raised $3.1M in pre-seed funding. The investment will be used to accelerate product developme... |
| 17.12.2024 | Akamis Bio Inks $60M Financing Round | CAMBRIDGE, MA, Akamis Bio today announced $60 million in funding round. >> Click here for more funding data on Akamis Bio >> To export Akamis Bio funding data to PDF and Excel, click here Akamis Bio, a clinical-stage oncology c... |